Rome Therapeutics
Ejecutivos
Ver el organigrama con sus 17 ejecutivos principales
Biografías más buscadas en Rome Therapeutics
- Rosana Kapeller, President, Chief Executive Officer and Director
- Jeff Hatfield, Chairman of the Board
- Steven Kafka, Director
Recientes movimientos de ejecutivos en Rome Therapeutics
- Heike Keilhack, se ha incorporado a la empresa como Chief Scientific Officer (noticia publicada el 5 de enero de 2024).
- Kyle Kuvalanka, se ha incorporado a la empresa como Chief Financial Officer and Chief Business Officer (noticia publicada el 5 de octubre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en Rome Therapeutics.
Biotecnología
Rome Therapeutics tiene 2.282 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Endeavor BioMedicines acaba de anunciar una recaudación de fondos de 132 millones de dólares. (publicado el 25 de abril de 2024).
- Metsera acaba de anunciar una recaudación de fondos de 290 millones de dólares. (publicado el 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado el 19 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Rome Therapeutics
- ROME Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference – ROME Therapeutics
- ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer – ROME Therapeutics
- ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery – ROME Therapeutics
- ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors – ROME Therapeutics
- Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium – ROME Therapeutics
- ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer – ROME Therapeutics
- ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease – ROME Therapeutics
- ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development – ROME Therapeutics
- ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease – ROME Therapeutics
- ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research – ROME Therapeutics
- View more press releases Close
Redes sociales sobre Rome Therapeutics
- Rome Therapeutics en Wikipedia, Google News y Yahoo Finance
- Rome Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Rosana Kapeller 
Llame a Rome Therapeutics al +1 617...
